With cutting-edge research in the fields of ENERGY, HEALTH and MATTER, around 1,500 employees from more than 70 nations at Helmholtz-Zentrum Dresden-Rossendorf (HZDR) are committed to mastering the great challenges facing society today.
The application of ultra-high-dose-rate radiotherapy (FLASH RT) promises reduced normal-tissue side effects while maintaining tumor cure rates similar to those of conventional radiotherapy. There is evidence that a combination of FLASH RT and immunotherapy may be synergistic. This interdisciplinary project is a collaboration among three HZDR institutes (Institute of Radiooncology – OncoRay, Institute of Radiation Physics and Institute of Radiopharmaceutical Cancer Research). The project aims to evaluate the efficacy of combined proton FLASH radiotherapy and CAR T-cell immunotherapy in vitro and in vivo and to characterize the molecular pathways and biomarkers explaining these effects.
At the Institute of Radiooncology – OncoRay scientists (f/m/d) specializing in medicine, physics, biology and IT work together to crucially improve the treatment of cancer by administering radiation therapy that is biologically-personalized and technically-optimized.
The scientists (f/m/d) at the Institute of Radiation Physics conduct research on states of matter under extreme conditions and in very small dimensions.
At the Institute of Radiopharmaceutical Cancer Research scientists (f/m/d) from the fields of physics, chemistry, biology, pharmacy, immunology, medicine and IT develop innovative radiopharmaceuticals and novel tools for functional characterization, improved imaging and personalized treatment of tumors.
The Department of Radiobiology, the Department of Laser Particle Acceleration, and the Department of Radioimmunology seek a
We look forward to receiving your application documents (including cover letter, CV, diplomas/transcripts, etc.), which you can submit via our online-application-system: https://www.hzdr.de/db/Cms?pNid=490&pLang=en&pOid=77663
ID: 204013